Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC? ...Middle East

News by : (Medscape) -
Nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical surgery for high-risk, muscle-invasive urothelial carcinoma, new research suggests. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC? )

Also on site :

Most Viewed News
جديد الاخبار